Literature DB >> 18575878

Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction.

Henny J M Beckers1, Jan S A G Schouten, Carroll A B Webers, Rikkert van der Valk, Fred Hendrikse.   

Abstract

BACKGROUND: To compare the tolerability of commonly prescribed topical glaucoma medications by determining frequency and bother of side effects, patient satisfaction with their medication, and the chance of discontinuation of eye drops.
METHODS: The tolerability of topical glaucoma medication was studied in glaucoma patients from nine hospitals. The frequency and severity of side effects was investigated together with patient satisfaction with the medication and the probability to change medication due to reported side effects. To register side effects of topical glaucoma medication, patients were requested to fill in a questionnaire based on "the Comparison of Ophthalmic Medications for Tolerability" (COMTOL) questionnaire supplemented with items based on the most frequently observed and severe side effects.
RESULTS: The number of patients responding was 3,333 (87%). Most patients (79%) were satisfied with their eye medication. The median score for ocular side effects was 58 on a scale ranging from 0 to 320. The probability that medication would be changed by the ophthalmologist at the next visit due to reported side effects occurring since the patients' last or last but one visit to the ophthalmologist was 9%. The most frequently prescribed drugs were timolol, latanoprost, and the fixed combinations of dorzolamide/timolol (Cosopt) and latanoprost/timolol (Xalcom). Only small differences in tolerability were found between these drugs.
CONCLUSIONS: The tolerability of timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom) and dorzolamide/timolol (Cosopt) seem to be comparable. Patients are satisfied with their glaucoma medication and have a low chance of discontinuation of eye drops due to side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575878     DOI: 10.1007/s00417-008-0875-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  18 in total

Review 1.  Update on topical carbonic anhydrase inhibitors.

Authors:  U Herkel; N Pfeiffer
Journal:  Curr Opin Ophthalmol       Date:  2001-04       Impact factor: 3.761

Review 2.  Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment.

Authors:  Paul J Lama
Journal:  Am J Ophthalmol       Date:  2002-11       Impact factor: 5.258

Review 3.  The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.

Authors:  Richard W Yee
Journal:  Curr Opin Ophthalmol       Date:  2007-03       Impact factor: 3.761

Review 4.  Travoprost/timolol.

Authors:  Sheridan M Hoy; Susan J Keam; Gillian M Keating
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Allergic reaction to topical eyedrops.

Authors:  Christophe Baudouin
Journal:  Curr Opin Allergy Clin Immunol       Date:  2005-10

Review 6.  Brimonidine (Alphagan): a clinical profile four years after launch.

Authors:  R David
Journal:  Eur J Ophthalmol       Date:  2001 Jul-Sep       Impact factor: 2.597

Review 7.  Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension.

Authors:  James E Frampton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 8.  Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.

Authors:  Dan L Eisenberg; Carol B Toris; Carl B Camras
Journal:  Surv Ophthalmol       Date:  2002-08       Impact factor: 6.048

Review 9.  The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.

Authors:  Eve J Higginbotham; M Diestelhorst; N Pfeiffer; J F Rouland; A Alm
Journal:  Surv Ophthalmol       Date:  2002-08       Impact factor: 6.048

10.  Predicting intraocular pressure change before initiating therapy: timolol versus latanoprost.

Authors:  Rikkert van der Valk; Carroll A B Webers; Fred Hendrikse; Stefan C de Vogel; Martin H Prins; Jan S A G Schouten
Journal:  Acta Ophthalmol       Date:  2007-11-17       Impact factor: 3.761

View more
  14 in total

Review 1.  Topical medication instillation techniques for glaucoma.

Authors:  Li Xu; Xuemei Wang; Meijing Wu
Journal:  Cochrane Database Syst Rev       Date:  2017-02-20

Review 2.  Neuropsychiatric Adverse Events from Topical Ophthalmic Timolol.

Authors:  Nevio Cimolai
Journal:  Clin Med Res       Date:  2019-08-28

3.  Short-term effect of topical brinzolamide-timolol fixed combination on ocular surface of glaucoma patients.

Authors:  Penpe Gul Firat; Emine Samdanci; Selim Doganay; Mufide Cavdar; Nurdan Sahin; Abuzer Gunduz
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

4.  Patient Medication Preferences for Managing Dry Eye Disease: The Importance of Medication Side Effects.

Authors:  Semra Ozdemir; Sharon Wan Jie Yeo; Jia Jia Lee; Adithya Bhaskar; Eric Finkelstein; Louis Tong
Journal:  Patient       Date:  2022-06-14       Impact factor: 3.481

5.  Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension.

Authors:  Nicholas P Bell; José L Ramos; Robert M Feldman
Journal:  Clin Ophthalmol       Date:  2010-11-22

6.  Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Authors:  Yoo C Kim; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-11       Impact factor: 4.799

7.  Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure - their disruption contributes to hypertensive glaucoma.

Authors:  Hanan Awad Alkozi; Gemma Navarro; David Aguinaga; Irene Reyes-Resina; Juan Sanchez-Naves; Maria J Pérez de Lara; Rafael Franco; Jesus Pintor
Journal:  Br J Pharmacol       Date:  2020-02-26       Impact factor: 8.739

8.  Preserved Versus Preservative-Free Latanoprost for the Treatment of Glaucoma and Ocular Hypertension: A Post Hoc Pooled Analysis.

Authors:  Paul Harasymowycz; Cindy Hutnik; Jean-François Rouland; Francisco J Muñoz Negrete; Mario A Economou; Philippe Denis; Christophe Baudouin
Journal:  Adv Ther       Date:  2021-04-23       Impact factor: 3.845

9.  Tolerability and effectiveness of preservative-free dorzolamide-timolol (preservative-free COSOPT) in patients with open-angle glaucoma or ocular hypertension.

Authors:  Cindy Hutnik; David Neima; Fahim Ibrahim; Robert Scott; Julie Vaillancourt; Denis Haine; John S Sampalis; Natacha Bastien; Sylvain Foucart
Journal:  Clin Ophthalmol       Date:  2010-07-21

10.  Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Henny J M Beckers; Jan Sag Schouten; Carroll A B Webers
Journal:  Clin Ophthalmol       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.